A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus (TAPINOMA)

Galapagos

Status and phase: Terminated; Phase 1

Conditions: Systemic Lupus Erythematosus

Treatments: Drug: Placebo film-coated tablet; Drug: GLPG3970 film-coated tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT04700267

GLPG3970-CL-102

2020-001820-32 (EudraCT Number)

Details and patient eligibility

About

This is a first exploration of GLPG3970 in subjects with active systemic lupus erythematosus (SLE) to evaluate the effect on disease biomarkers and to determine its pharmacokinetics (PK) profile, safety and tolerability, and pharmacodynamics (PD) biomarkers related to the investigational product (IP) mechanism of action and the pathophysiology of SLE.

Enrollment: 11 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• SLE diagnosis defined by American College of Rheumatology (ACR) 1997 criteria ≥4

• Active arthritis in >=4 active joints (according to 28 joint count) and/or cutaneous lupus erythematosus disease area and severity index (CLASI) score >=6.

• Anti-dsDNA antibodies >15 IU/mL.

• Stable standard-of-care (SoC) therapy (defined as no change in prescription for at least 2 weeks prior to first IP dosing) consisting of the following permitted SoC medications:

  • Corticosteroids <=20 mg/day (prednisone or equivalent) for at least 2 weeks prior to first IP dosing; AND/OR
  • Non-steroidal anti-inflammatory drug (NSAIDs); AND/OR
  • One single antimalarial at a stable dose (hydroxychloroquine <=5 mg/ kg/day, quinacrine 100 mg/day, or chloroquine 2.3 mg/kg/day) for at least 8 weeks prior to first IP dosing; AND/OR
  • One single immunosuppressant at a stable dose (azathioprine (AZA) <=2 mg/kg/day, methotrexate (MTX) <=20 mg/week, or mycophenolate mofetil (MMF) <=2 g/day) for at least 8 weeks prior to first IP dosing.

• estimated glomerular filtration rate (eGFR) >=60 mL/min (according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI))

This list only contains the key inclusion criteria.

Exclusion criteria

• Lupus nephritis >= Class III
• Severe organ manifestation or life-threatening lupus disease (active severe central nervous system lupus, severe pleuro-pericarditis, severe vasculitis).
• Severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection >0
• Unstable condition not related to SLE
• Systemic inflammatory condition other than SLE such as, but not limited to rheumatoid arthritis (RA), spondyloarthropathy, Crohn's disease, ulcerative colitis, or psoriatic arthritis
• Sjögren's syndrome and/or antiphospholipid antibody syndrome who do not require treatment with any prohibited medication are NOT excluded.
• Active systemic infection
• Poorly controlled chronic cardiac, pulmonary, or renal disease.
• Known or suspected history of or a current immunosuppressive condition, or a history of invasive opportunistic infections
• Treatment with disallowed therapies

This list only contains the key exclusion criteria.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

11 participants in 2 patient groups, including a placebo group

GLPG3970

Experimental group

Description:

One dose level of GLPG3970

Treatment:

Drug: GLPG3970 film-coated tablet

Placebo

Placebo Comparator group

Description:

One dose level of Placebo

Treatment:

Drug: Placebo film-coated tablet